Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
1999 1
2000 1
2002 1
2003 1
2005 1
2006 1
2007 2
2013 1
2014 1
2015 2
2016 1
2017 1
2018 4
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.
Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, Zhang ZY, Hanke J, Ramaswamy S, Wang J. Sun K, et al. Among authors: mikule k. Oncotarget. 2018 Dec 14;9(98):37080-37096. doi: 10.18632/oncotarget.26354. eCollection 2018 Dec 14. Oncotarget. 2018. PMID: 30647846 Free PMC article.
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Carey JPW, et al. Among authors: mikule k. Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27. Cancer Res. 2018. PMID: 29180466 Free PMC article.
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, Mills GB, Hanke J, Ramaswamy S, Wang J. Wang Z, et al. Among authors: mikule k. Sci Rep. 2019 Feb 12;9(1):1853. doi: 10.1038/s41598-019-38534-6. Sci Rep. 2019. PMID: 30755715 Free PMC article.
Suppression of cancer relapse and metastasis by inhibiting cancer stemness.
Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, Leggett D, Li W, Pardee AB, Li CJ. Li Y, et al. Among authors: mikule k. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi: 10.1073/pnas.1424171112. Epub 2015 Jan 20. Proc Natl Acad Sci U S A. 2015. PMID: 25605917 Free PMC article.
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Póti Á, Berta K, Xiao Y, Pipek O, Klus GT, Ried T, Csabai I, Wilcoxen K, Mikule K, Szallasi Z, Szüts D. Póti Á, et al. Among authors: mikule k. Br J Cancer. 2018 Nov;119(11):1392-1400. doi: 10.1038/s41416-018-0312-6. Epub 2018 Nov 14. Br J Cancer. 2018. PMID: 30425352 Free PMC article.
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.
Wang Z, Grosskurth SE, Cheung T, Petteruti P, Zhang J, Wang X, Wang W, Gharahdaghi F, Wu J, Su N, Howard RT, Mayo M, Widzowski D, Scott DA, Johannes JW, Lamb ML, Lawson D, Dry JR, Lyne PD, Tate EW, Zinda M, Mikule K, Fawell SE, Reimer C, Chen H. Wang Z, et al. Among authors: mikule k. Cancer Res. 2018 Dec 1;78(23):6691-6702. doi: 10.1158/0008-5472.CAN-18-1362. Epub 2018 Oct 8. Cancer Res. 2018. PMID: 30297535 Free article.
Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models.
Sambade MJ, Van Swearingen AED, McClure MB, Deal AM, Santos C, Sun K, Wang J, Mikule K, Anders CK. Sambade MJ, et al. Among authors: mikule k. Neurooncol Adv. 2019 Jun 4;1(1):vdz005. doi: 10.1093/noajnl/vdz005. eCollection 2019 May-Dec. Neurooncol Adv. 2019. PMID: 32642648 Free PMC article.
Centrosome control of the cell cycle.
Doxsey S, Zimmerman W, Mikule K. Doxsey S, et al. Among authors: mikule k. Trends Cell Biol. 2005 Jun;15(6):303-11. doi: 10.1016/j.tcb.2005.04.008. Trends Cell Biol. 2005. PMID: 15953548 Review.
Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.
Johannes JW, Almeida L, Daly K, Ferguson AD, Grosskurth SE, Guan H, Howard T, Ioannidis S, Kazmirski S, Lamb ML, Larsen NA, Lyne PD, Mikule K, Ogoe C, Peng B, Petteruti P, Read JA, Su N, Sylvester M, Throner S, Wang W, Wang X, Wu J, Ye Q, Yu Y, Zheng X, Scott DA. Johannes JW, et al. Among authors: mikule k. Bioorg Med Chem Lett. 2015 Dec 15;25(24):5743-7. doi: 10.1016/j.bmcl.2015.10.079. Epub 2015 Oct 27. Bioorg Med Chem Lett. 2015. PMID: 26546219
Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.
Gu C, Lamb ML, Johannes JW, Sylvester MA, Eisman MS, Harrison RA, Hu H, Kazmirski S, Mikule K, Peng B, Su N, Wang W, Ye Q, Zheng X, Lyne PD, Scott DA. Gu C, et al. Among authors: mikule k. Bioorg Med Chem Lett. 2016 Oct 1;26(19):4775-4780. doi: 10.1016/j.bmcl.2016.08.030. Epub 2016 Aug 12. Bioorg Med Chem Lett. 2016. PMID: 27578247
21 results
Jump to page
Feedback